SCHEMBL29299583

SCHEMBL29299583

CC(C)CCCNC(=O)[C@H](N)CCCNC(C)C

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.56
GNAI3 P08754 1/20 0.49
GNAO1 P09471 1/20 0.49
GNAI1 P63096 1/20 0.49
RRM1 P23921 1/20 0.47
ANPEP P15144 3/20 0.42
RNPEP Q9H4A4 2/20 0.42
DNPEP Q9ULA0 2/20 0.42
SLC15A1 P46059 1/20 0.40
NOD1 Q9Y239 1/20 0.39
NOS1 P29475 1/20 0.37
OTC P00480 1/20 0.36
S1PR2 O95136 2/20 0.36
S1PR1 P21453 2/20 0.36
S1PR3 Q99500 2/20 0.36
S1PR5 Q9H228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29299582 1.00 DPP7 (0.56) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29300155 0.97 DPP7 (0.57) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29299854 0.97 DPP7 (0.57) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29299837 0.95 DPP7 (0.58) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29299858 0.93 DPP7 (0.51) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29300262 0.87 DPP7 (0.76) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL24712698 0.85 GNAI3 (0.63) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29299623 0.85 DPP7 (0.57) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL29300377 0.85 GNAI3 (0.62) DPP7GNAI3GNAO1GNAI1RRM1
SCHEMBL24712492 0.84 DPP7 (0.54) DPP7GNAI3GNAO1GNAI1RRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R DPP7 1196/4885GNAI3 1655/4885GNAO1 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.